Loading company…
Ractigen Therapeutics develops RNA activation medicines and gene expression technologies for disease treatment.
Founded in 2016 and based in Nantong, China, Ractigen Therapeutics develops RNA activation therapies and gene expression technologies for genetic diseases, cancer, liver conditions, and central nervous system disorders. Its pipeline includes RAG-06, RAG-01, RAG-11, and RAG-03, supported by its Smart-TTC and SCAD platforms. In July 2026, it raised over CNY 200 million in venture funding led by Shenzhen Guozhong Venture Capital, with participation from IDG Capital, China Everbright, Jolmo Capital, SND Ventures Group, Puying Group, Zhuhai Longmen Capital Management, and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in